ccRCC

:   clear cell renal cell carcinoma

LncRNAs

:   Long non-coding RNAs

HIF

:   hypoxia-inducible factors

VHL

:   von Hippel-Lindau

snoRNAs

:   small nucleolar RNAs (snoRNAs)

SNHGs

:   small nucleolar RNA host genes

OS

:   Overall Survival

RFS

:   Relapse-Free Survival

TCGA

:   The Cancer Genome Atlas

INTRODUCTION
============

Renal cell carcinoma (RCC) is one of the most aggressive cancers of the urinary system, accounting for approximately 4% of adult malignancies \[[@r1]\]. The most common histologic subtype clear cell RCC (ccRCC) accounts for approximately 75-80% of RCC, and up to 92% of these cancers have VHL protein inactivation \[[@r2]--[@r4]\]. Mutations and inactivation of VHL lead to accumulation of HIF-α proteins and upregulation of HIF-α target genes, which has been considered as a key mechanism to promote the progression of ccRCC \[[@r5]\]. In spite of recent advances in the comprehensive treatments like surgical operation, molecular targeted therapy, chemotherapy and radiation treatment, the 5-year overall survival rate for metastatic ccRCC patients remains as low as 10% to 20% \[[@r6]\]. Therefore, it is imperative to identify new biomarkers and therapeutic targets for ccRCC.

With the development of high-throughput transcriptome analysis in recent years, it has been found that over 90% of the total mammalian genome can be transcribed but does not encode proteins \[[@r7]\]. As a new class of non-coding RNA (ncRNA), long ncRNAs (lncRNAs) longer than 200 nucleotides have been found to be aberrantly expressed in some diseases, particularly in cancer \[[@r8], [@r9]\]. Although lncRNAs are not involved in protein-coding, they can regulate gene expression at the level of chromatin modification, transcription and post-transcriptional processing \[[@r10]\]. In addition, emerging studies indicate that lncRNAs are differentially expressed in ccRCC and exert critical regulatory effects on a series of cellular processes, such as proliferation, apoptosis and metastasis \[[@r11], [@r12]\].

Some lncRNAs can encode small nucleolar RNAs (snoRNAs), called small nucleolar RNA host genes (SNHGs). snoRNAs have been considered to be one of the best characterized classes of non-coding RNAs (ncRNAs) with a wide variety of cellular functions, such as chemical RNA modifications (such as methylations and pseudouridylations), pre-RNA processing and alternative splicing control \[[@r13]--[@r15]\]. In addition, some snoRNAs have shown differential expression patterns in various human cancers, as well as the ability to affect cell transformation, tumorigenesis, and metastasis \[[@r16]--[@r18]\]. For instance, SNORA21 showed oncogenic properties in human colorectal cancer, and elevated SNORA21 served as an independent factor for predicting poor survival \[[@r19]\]; SNORA42 expression was an independent prognostic factor for overall survival and disease-free survival of colorectal cancer \[[@r20]\]. Thus, the SNHGs, as the host genes of snoRNAs, may have multiple regulatory effects on tumor cell processes and play crucial roles in cancer.

Consistent with the above researches, several recent studies have demonstrated that the SNHGs might be valuable prognostic markers in some cancers. GAS5 could inhibit the progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation \[[@r21]\]; SNHG15 interacted with and stabilized transcription factor Slug and promoted colon cancer progression \[[@r22]\]; Higher SNHG20 expression was significantly associated with advanced tumor, lymph node and metastases (TNM) stage and tumor size, as well as poorer overall survival \[[@r23]\]. However, there has been relatively little research on the clinical roles of SNHGs in ccRCC specifically. In this study, using RNA-seq and survival data in the Cancer Genome Atlas (TCGA)-Kidney Renal Clear Cell Carcinoma (KIRC), we examined the expression profile of some SNHGs and explored their prognostic values in ccRCC, followed by validation in a certain number of paired clinical samples (adjacent normal renal tissue and ccRCC).

RESULTS
=======

The identification of differentially expressed lncRNAs encoding snoRNAs in ccRCC
--------------------------------------------------------------------------------

In TCGA-KIRC cohort, tumor tissues from 539 cases of ccRCC were subjected to RNA-seq study, among which 72 cases had matched adjacent normal tissues ([Figure 1](#f1){ref-type="fig"}). Using RNA-seq data in TCGA-KIRC, we compared the expression of lncRNAs encoding snoRNAs between ccRCC tissues and the matched adjacent normal tissues. Results showed that compared with adjacent normal tissues, SNHG1, GAS5, SNHG3-8, SNHG11, SNHG12, SNHG15-17, SNHG20, SNHG22 and SNHG25 were significantly upregulated in ccRCC tissues, while SNHG9, SNHG10, DANCR and SNHG14 were remarkably downregulated in ccRCC tissues ([Figure 2A](#f2){ref-type="fig"}--[2C](#f2){ref-type="fig"}).

![**Patient inclusion and data availability.**](aging-12-102894-g001){#f1}

![**Expression profiles of lncRNAs encoding snoRNA in ccRCC.** (**A**) Heatmap, (**B**, **C**) Plots chart showing the expression profile of correlation between SNHG1, GAS5, SNHG3-12, DANCR, SNHG14-17, SNHG20, SNHG22 and SNHG25 between ccRCC tissues and matched adjacent (adj.) normal (AN) tissues.](aging-12-102894-g002){#f2}

Association between lncRNAs encoding snoRNAs and survival of ccRCC patients
---------------------------------------------------------------------------

To explore the prognostic values of lncRNAs encoding snoRNAs, we used the TCGA-Clinical data to analyze their relevances with the Overall Survival (OS) and Relapse-Free survival (RFS) among ccRCC patients by generating Kaplan--Meier survival curves ([Figure 1](#f1){ref-type="fig"}), and the detailed clinical characteristics of patients with ccRCC in TCGA were shown in [Table 1](#t1){ref-type="table"}. Results of the log-rank test showed that the high expression groups of SNHG3, SNHG4, SNHG12, SNHG15, SNHG17 and SNHG25 had significantly shorter OS, while high SNHG5 and SNHG8 expression groups had remarkably longer OS ([Figure 3A](#f3){ref-type="fig"}). Moreover, results of the log-rank test also showed that the high SNHG15 expression group had significantly shorter RFS than its low expression group ([Figure 3B](#f3){ref-type="fig"}).

###### The clinical characteristics of 530 ccRCC patients in TCGA.

  --------------------------------------- ----------- ------------
  **Clinicopathologic characteristics**   **n (%)**   
                                                      
  Age                                                 
                                          \<60        245 (46.2)
                                          \>=60       285 (53.8)
  Overall Survival                                    
                                          Alive       373 (70.4)
                                          Dead        157 (29.6)
  Gender                                              
                                          Male        344 (64.9)
                                          Female      186 (35.1)
  Tumor stage                                         
                                          T1/T2       340 (64.2)
                                          T3/T4       190 (35.8)
  Lymphatic invasion                                  
                                          N0          239 (45.1)
                                          N1          16 (3.0)
                                          NX          275 (51.9)
  Metastasis                                          
                                          M0          440 (83.0)
                                          M1          80 (15.1)
                                          MX          10 (1.9)
  Pathological stage                                  
                                          I/II        322 (61.1)
                                          III/IV      205 (38.9)
  Historical grade                                    
                                          G1/G2       241 (45.7)
                                          G3/G4       286 (54.3)
  --------------------------------------- ----------- ------------

![**Kaplan--Meier curves of OS and RFS in patients with ccRCC.** (**A**) Patients were grouped according to the median cutoff of SNHG3, SNHG4, SNHG5, SNHG8, SNHG12, SNHG15, SNHG17 and SNHG25 expression for OS detection. (**B**) Patients were grouped according to the median cutoff of SNHG15 expression for RFS detection.](aging-12-102894-g003){#f3}

In univariate analysis, advanced tumor stage/pathological stage/histological grade, metastasis, increased SNHG3/SNHG4 expression and decreased SNHG5/SNHG8 expression were potential risk factors of shorter OS. After adjustment for confounding factors, the multivariate analysis indicated that only advanced pathological stage, metastasis and increased SNHG3 expression were independently associated with shorter OS in ccRCC patients ([Table 2](#t2){ref-type="table"}). In terms of RFS, advanced tumor stage/pathological stage/histological grade, metastasis and increased SNHG15 expression were potential risk factors of shorter RFS. Moreover, the following multivariate analysis showed that advanced pathological stage/histological grade, metastasis and increased SNHG15 expression were independent predictors of shorter RFS in ccRCC patients ([Table 3](#t3){ref-type="table"}).

###### Univariate and multivariate analysis of OS in patients with ccRCC.

  ------------------------ ------------------------- --------------------------- ----------- -------- -------------- ----------- ----------- --------
  **Parameters**           **Univariate analysis**   **Multivariate analysis**                                                               
  **P**                    **HR**                    **95%CI**                   **P**       **HR**   **95%CI**                              
                                                     **Lower**                   **Upper**                           **Lower**   **Upper**   
  **Age(Continuous)**      0.4410                    1.1280                      0.8306      1.5310                                          
  **Gender**                                                                                                                                 
  Male                                               1.0000                                                                                  
  Female                   0.8190                    1.0380                      0.7555      1.4260                                          
  **Tumor stage**                                                                                                                            
  T1/T2                                              1.0000                                                                                  
  T3/T4                    **\<0.0001**              3.2030                      2.3470      4.3680   0.8367         0.9364      0.5014      1.7490
  **Metastasis**                                                                                                                             
  No                                                 1.0000                                                                                  
  yes                      **\<0.0001**              4.4130                      3.2270      6.0350   **\<0.0001**   2.6229      1.7469      3.9380
  **Pathological stage**                                                                                                                     
  I/II                                               1.0000                                                                                  
  III/IV                   **\<0.0001**              3.8760                      2.8010      5.3630   **0.0071**     2.6986      1.3103      5.5580
  **Histological grade**                                                                                                                     
  G1/G2                                              1.0000                                                                                  
  G3/G4                    **0.0236**                1.4390                      1.0500      1.9720   0.0780         0.7172      0.4956      1.0380
  **SNHG3**                **0.0008**                2.4240                      2.0543      2.9474   **0.0362**     1.3401      1.0556      1.7010
  **SNHG4**                **0.0178**                1.3300                      1.0510      1.6830   0.4216         1.1586      0.8091      1.6590
  **SNHG5**                **0.0011**                0.7783                      0.6698      0.9044   0.0631         0.8366      0.6931      1.0100
  **SNHG8**                **0.0146**                0.7908                      0.6551      0.9547   0.6159         0.9400      0.7382      1.1970
  SNHG12                   0.2140                    1.0980                      0.9473      1.2730                                          
  SNHG15                   0.1050                    1.1830                      0.9655      1.4510                                          
  SNHG17                   0.1630                    1.1810                      0.9349      1.4910                                          
  SNHG25                   0.1590                    1.1240                      0.9550      1.3240                                          
  ------------------------ ------------------------- --------------------------- ----------- -------- -------------- ----------- ----------- --------

###### Univariate and multivariate analysis of RFS in patients with ccRCC.

  ------------------------ ------------------------- --------------------------- ----------- --------- -------------- ----------- ----------- ---------
  **Parameters**           **Univariate analysis**   **Multivariate analysis**                                                                
  **P**                    **HR**                    **95%CI**                   **P**       **HR**    **95%CI**                              
                                                     **Lower**                   **Upper**                            **Lower**   **Upper**   
  **Age (Continuous)**     0.8050                    1.0020                      0.9864      1.0180                                           
  **Gender**                                                                                                                                  
   Male                                              1.0000                                                                                   
   Female                  0.0680                    0.6767                      0.4449      1.0290                                           
  **Tumor stage**                                                                                                                             
   T1/T2                                             1.0000                                                                                   
   T3/T4                   **\<0.0001**              4.5180                      3.0690      6.6510    0.1967         0.6334      0.3167      1.2669
  **Metastasis**                                                                                                                              
   No                                                1.0000                                                                                   
   yes                     **\<0.0001**              12.0300                     8.0760      17.9100   **\<0.0001**   4.6964      2.9147      7.5673
  **Pathological stage**                                                                                                                      
   I/II                                              1.0000                                                                                   
   III/IV                  **\<0.0001**              6.8300                      4.4650      10.4500   **0.0002**     4.8308      2.1181      11.0177
  **Histological grade**                                                                                                                      
   G1/G2                                             1.0000                                                                                   
   G3/G4                   **\<0.0001**              3.3350                      2.1480      5.1760    **0.0190**     1.7529      1.0966      2.8020
  **SNHG15**               **0.0010**                1.5440                      1.1920      2.0000    **0.0248**     1.3750      1.0412      1.8158
  ------------------------ ------------------------- --------------------------- ----------- --------- -------------- ----------- ----------- ---------

In addition, these SNHGs expression were closely related to some clinical parameters of ccRCC, including tumor stage, lymphatic invasion, metastasis, pathological stage and histological grade ([Table 4](#t4){ref-type="table"}, [Figure 4](#f4){ref-type="fig"}). Compared with early-stage (T1/T2) ccRCC, the expression levels of SNHG3, SNHG4, SNHG15 and SNHG17 were significantly higher in advanced-stage (T3/T4) ccRCC. Moreover, SNHG3, SNHG4 and SNHG15 were highly expressed in high histological grade ccRCC compared to low histological grade ccRCC. Furthermore, the expression levels of SNHG3 and SNHG15 in ccRCC with remote metastasis were remarkably higher.

###### The correlation between SNHGs expression and the clinical characteristics of ccRCC patients in TCGA-KIRC.

  -------------------- ----------------- ------------------------ -------------------- ------------------------ ------------------------ ------------ ------------ ----------- ------------ --------------
  **lncRNAs**          **Tumor stage**   **Lymphatic invasion**   **Metastasis**       **Pathological stage**   **Histological grade**                                                      
  **T1/T2 vs.T3/T4**   **No vs.Yes**     **No vs.Yes**            **I/II vs.III/IV**   **G1/G2 vs.G3/G4**                                                                                   
  **t**                **p**             **t**                    **p**                **t**                    **p**                    **t**        **p**        **t**       **p**        
  **SNHG3**            **-3.181**        **0.002**                **-2.195**           **0.043**                **-2.971**               **0.004**    -1.390       0.165       **-1.994**   **0.047**
  **SNHG4**            **-2.796**        **0.005**                -2.017               0.061                    -1.679                   0.096        -0.909       0.364       **-2.824**   **0.005**
  **SNHG5**            **2.062**         **0.040**                3.943                0.001                    1.258                    0.211        1.105        0.270       **2.638**    **0.0086**
  **SNHG8**            **5.690**         **\<0.0001**             **2.462**            **0.023**                **2.389**                **0.019**    **2.453**    **0.015**   **5.891**    **\<0.0001**
  **SNHG12**           -1.532            0.127                    -1.429               0.172                    -1.839                   0.070        0.347        0.729       -0.931       0.3522
  **SNHG15**           **-3.943**        **\<0.0001**             -0.180               0.859                    **-3.658**               **0.0004**   **-3.506**   **0.001**   **-2.472**   **0.0138**
  **SNHG17**           **-3.036**        **0.003**                -1.406               0.178                    **-2.560**               **0.012**    -1.370       0.171       -1.559       0.1197
  **SNHG25**           -1.556            0.121                    -1.439               0.169                    -1.922                   0.057        **-2.162**   **0.031**   **-2.444**   **0.0149**
  -------------------- ----------------- ------------------------ -------------------- ------------------------ ------------------------ ------------ ------------ ----------- ------------ --------------

![**The correlation between SNHGs expression and the clinical characteristics of ccRCC patients.** The correlation between SNHGs expression and tumor stage, lymphatic invasion, histological grade, pathological stage and metastasis.](aging-12-102894-g004){#f4}

SNHG3 and SNHG15 expression was regulated by DNA methylation
------------------------------------------------------------

In TCGA-KIRC, 325 ccRCC tissues samples and 160 adjacent normal tissues samples were subjected to DNA methylation analysis simultaneously ([Figure 1](#f1){ref-type="fig"}). Using the methylation data obtained from the Infinium Human Methylation450 BeadChip, we compared the methylation status of 12 CpG sites in SNHG3 DNA, 13 CpG sites in SNHG15 DNA, 22 CpG sites in SNHG12 DNA and 24 CpG sites in SNHG17 DNA ([Table 5](#t5){ref-type="table"}). The heatmap constructed on beta values of these CpG sites across all 485 samples was shown in [Figure 5A](#f5){ref-type="fig"}--[5D](#f5){ref-type="fig"}. The analysis results showed that compared with adjacent normal tissues, 2 sites of SNHG3 DNA, 3 sites of SNHG15 DNA, 6 sites of SNHG12 DNA and 8 sites of SNHG17 DNA were significantly hypomethylated in ccRCC ([Figure 5E](#f5){ref-type="fig"}--[5H](#f5){ref-type="fig"}).

###### The detailed information of CpG sites of SNHG3, SNHG15, SNHG12 and SNHG17 DNA.

  --------------------------- ---------------- ----------- ---------- -----------------------------
  **Composite element REF**   **Chromosome**   **Start**   **End**    **CGI_Coordinate**
  **SNHG3**                                                           
  cg07807470                  chr1             28510838    28510839   CGI:chr1:28518141-28518781
  cg08935021                  chr1             28506029    28506030   CGI:chr1:28518141-28518781
  cg10700647                  chr1             28506126    28506127   CGI:chr1:28518141-28518781
  cg15161854                  chr1             28509627    28509628   CGI:chr1:28518141-28518781
  cg16013246                  chr1             28505956    28505957   CGI:chr1:28518141-28518781
  cg16013618                  chr1             28507076    28507077   CGI:chr1:28518141-28518781
  cg22238707                  chr1             28506552    28506553   CGI:chr1:28518141-28518781
  cg23738833                  chr1             28505869    28505870   CGI:chr1:28518141-28518781
  cg24469114                  chr1             28506476    28506477   CGI:chr1:28518141-28518781
  cg25775721                  chr1             28505362    28505363   CGI:chr1:28518141-28518781
  cg26419621                  chr1             28507275    28507276   CGI:chr1:28518141-28518781
  cg26793226                  chr1             28506061    28506062   CGI:chr1:28518141-28518781
  **SNHG15**                                                          
  cg00762623                  chr7             44986421    44986422   CGI:chr7:44986359-44987027
  cg00953154                  chr7             44986021    44986022   CGI:chr7:44986359-44987027
  cg02422847                  chr7             44986984    44986985   CGI:chr7:44986359-44987027
  cg02698620                  chr7             44986980    44986981   CGI:chr7:44986359-44987027
  cg03440944                  chr7             44983730    44983731   CGI:chr7:44986359-44987027
  cg06057141                  chr7             44986818    44986819   CGI:chr7:44986359-44987027
  cg07097673                  chr7             44986749    44986750   CGI:chr7:44986359-44987027
  cg11881910                  chr7             44986660    44986661   CGI:chr7:44986359-44987027
  cg12393589                  chr7             44988044    44988045   CGI:chr7:44986359-44987027
  cg16459265                  chr7             44985481    44985482   CGI:chr7:44986359-44987027
  cg18205465                  chr7             44986944    44986945   CGI:chr7:44986359-44987027
  cg18544085                  chr7             44986751    44986752   CGI:chr7:44986359-44987027
  cg22557029                  chr7             44986812    44986813   CGI:chr7:44986359-44987027
  **SNHG12**                                                          
  cg00261162                  chr1             28580966    28580967   CGI:chr1:28581557-28582287
  cg01198591                  chr1             28582493    28582494   CGI:chr1:28581557-28582287
  cg03542031                  chr1             28579698    28579699   CGI:chr1:28581557-28582287
  cg04206337                  chr1             28581041    28581042   CGI:chr1:28581557-28582287
  cg04872869                  chr1             28582125    28582126   CGI:chr1:28581557-28582287
  cg07033395                  chr1             28580026    28580027   CGI:chr1:28581557-28582287
  cg07944736                  chr1             28581714    28581715   CGI:chr1:28581557-28582287
  cg09513672                  chr1             28582258    28582259   CGI:chr1:28581557-28582287
  cg10053149                  chr1             28581997    28581998   CGI:chr1:28581557-28582287
  cg11191040                  chr1             28581122    28581123   CGI:chr1:28581557-28582287
  cg11573859                  chr1             28581227    28581228   CGI:chr1:28581557-28582287
  cg11753765                  chr1             28582446    28582447   CGI:chr1:28581557-28582287
  cg12640482                  chr1             28579061    28579062   CGI:chr1:28581557-28582287
  cg15160573                  chr1             28582130    28582131   CGI:chr1:28581557-28582287
  cg15601452                  chr1             28579870    28579871   CGI:chr1:28581557-28582287
  cg16724557                  chr1             28581391    28581392   CGI:chr1:28581557-28582287
  cg17459893                  chr1             28582020    28582021   CGI:chr1:28581557-28582287
  cg19265143                  chr1             28581125    28581126   CGI:chr1:28581557-28582287
  cg19712659                  chr1             28579844    28579845   CGI:chr1:28581557-28582287
  cg20497554                  chr1             28581859    28581860   CGI:chr1:28581557-28582287
  cg22033189                  chr1             28582039    28582040   CGI:chr1:28581557-28582287
  cg26328951                  chr1             28580002    28580003   CGI:chr1:28581557-28582287
  **SNHG17**                                                          
  cg00615913                  chr20            38434453    38434454   CGI:chr20:38434882-38435463
  cg01153946                  chr20            38433978    38433979   CGI:chr20:38434882-38435463
  cg03079640                  chr20            38435631    38435632   CGI:chr20:38434882-38435463
  cg03260166                  chr20            38431074    38431075   CGI:chr20:38434882-38435463
  cg04560741                  chr20            38427432    38427433   CGI:chr20:38434882-38435463
  cg04981166                  chr20            38428775    38428776   CGI:chr20:38434882-38435463
  cg06473773                  chr20            38435086    38435087   CGI:chr20:38434882-38435463
  cg07234199                  chr20            38431182    38431183   CGI:chr20:38434882-38435463
  cg08271622                  chr20            38425321    38425322   CGI:chr20:38434882-38435463
  cg09744151                  chr20            38429772    38429773   CGI:chr20:38434882-38435463
  cg11363483                  chr20            38429853    38429854   CGI:chr20:38434882-38435463
  cg11609780                  chr20            38431293    38431294   CGI:chr20:38434882-38435463
  cg13610455                  chr20            38426257    38426258   CGI:chr20:38434882-38435463
  cg15199754                  chr20            38435363    38435364   CGI:chr20:38434882-38435463
  cg16754665                  chr20            38435462    38435463   CGI:chr20:38434882-38435463
  cg17308044                  chr20            38435758    38435759   CGI:chr20:38434882-38435463
  cg19077271                  chr20            38435352    38435353   CGI:chr20:38434882-38435463
  cg19197795                  chr20            38435356    38435357   CGI:chr20:38434882-38435463
  cg19537490                  chr20            38428539    38428540   CGI:chr20:38434882-38435463
  cg23747525                  chr20            38435446    38435447   CGI:chr20:38434882-38435463
  cg24310959                  chr20            38426237    38426238   CGI:chr20:38434882-38435463
  cg24629392                  chr20            38428723    38428724   CGI:chr20:38434882-38435463
  cg24832710                  chr20            38435451    38435452   CGI:chr20:38434882-38435463
  cg27628552                  chr20            38435861    38435862   CGI:chr20:38434882-38435463
  --------------------------- ---------------- ----------- ---------- -----------------------------

![**Comparison of SNHG3, SNHG15, SNHG12 and SNHG17 DNA methylation in ccRCC and adjacent normal tissues.** (**A**--**D**) Heatmaps and (**E**--**H**) statistical comparison of the difference in methylation in CpG sites of SNHG3, SNHG15, SNHG12 and SNHG17 DNA, between 325 ccRCC and 160 adjacent normal tissues.](aging-12-102894-g005){#f5}

To further explore the potential regulatory effect of DNA methylation on SNHG3, SNHG15, SNHG12 and SNHG17 expression, we analyzed the correlation between the 4 lncRNAs expression and the methylation status of their CpG sites. Correlation analysis results showed that the expressions of SNHG3, SNHG15, SNHG12 and SNHG17 were negatively associated with the methylation levels of 2 sites (cg07807470 r=-0.1963, cg15161854 r=-0.2752), 3 sites (cg00953154 r=-0.4113, cg03440944 r=-0.3342, cg16459265 r=-0.4082), 6 sites (cg03542031 r=-0.5038, cg07033395 r=-0.394, cg12640482 r=-0.3214, cg15601452 r=-0.3814, cg19712659 r=-0.5023, cg26328951 r=-0.4231) and 3 sites (cg04560741 r=-0.1919, cg13610455 r=-0.2631, cg24310959 r=-0.2744), respectively ([Figure 6A](#f6){ref-type="fig"}--[6D](#f6){ref-type="fig"}). Moreover, results of the log-rank test showed that low methylation levels of cg07807470 (SNHG3), cg15161854 (SNHG3), cg00953154 (SNHG15), cg16459265 (SNHG15) and cg07033395 (SNHG12) were significantly associated with the shorter OS of ccRCC patients ([Figure 6E](#f6){ref-type="fig"}--[6G](#f6){ref-type="fig"}). Furthermore, low methylation levels of cg07807470 (SNHG3), cg15161854 (SNHG3) and cg16459265 (SNHG15) were also related to the shorter RFS ([Figure 6H](#f6){ref-type="fig"}, [6I](#f6){ref-type="fig"}). Taken together, these results indicated that the expressions of SNHG3 and SNHG15 were more likely to be modulated by DNA methylation in ccRCC.

![**The prognostic value of CpG sites that are negatively correlated with SNHG3, SNHG15, SNHG12 and SNHG17 expression.** (**A**) The correlation between SNHG3 expression and the methylation status of cg07807470 and cg15161854. (**B**) The correlation between SNHG15 expression and the methylation status of cg00953154, cg03440944 and cg16459265. (**C**) The correlation between SNHG12 expression and the methylation status of cg03542031, cg07033395, cg12640482, cg15601452, cg19712659 and cg26328951. (**D**) The correlation between SNHG12 expression and the methylation status of cg04560741, cg13610455 and cg24310959. (**E**--**G**) Patients were grouped according to the median cutoff of cg07807470, cg15161854, cg00953154, cg16459265 and cg0703395 methylation status for OS detection. (**H**--**I**) Patients were grouped according to the median cutoff of cg07807470, cg15161854 and cg16459265 methylation status for RFS detection.](aging-12-102894-g006){#f6}

The validation of the expression patterns and the DNA methylation status of SNHG3 and SNHG15 based on clinical samples
----------------------------------------------------------------------------------------------------------------------

62 paired clinical samples were utilized to validate the expression patterns of SNHG3 and SNHG15, and 15 paired clinical samples were used to examine the DNA methylation status of 4 CpG sites (cg07807470, cg15161854, cg00953154, cg16459265) ([Figure 1](#f1){ref-type="fig"}), and the clinical information of these 62 ccRCC patients are also showed in [Table 6](#t6){ref-type="table"}. q-RT-PCR was performed to confirm the expression of SNHG3 and SNHG15 in these 62 paired clinical samples. Consistent with the results from TCGA datasets, the expression levels of SNHG3 and SNHG15 were remarkably higher in ccRCC tissues than that of adjacent normal renal tissues ([Figure 7A](#f7){ref-type="fig"}). Results of the log-rank test showed that high expression of SNHG3 and SNHG15 was associated with the shorter OS, and high expression of SNHG15 was also related to the shorter RFS. Moreover, the expression levels of SNHG3 and SNHG15 were significantly higher in advanced-stage ccRCC than in early-stage ccRCC ([Figure 7B](#f7){ref-type="fig"}).

###### The clinical characteristics of 62 ccRCC patients used for validation.

  --------------------------------------- -----------
  **Clinicopathologic characteristics**   **n (%)**
  Age                                     
   \<60                                   33 (53.2)
   \>=60                                  29 (46.8)
  Overall Survival                        
   Alive                                  42 (67.7)
   Dead                                   20 (32.3)
  Tumor size                              
   \< 2cm                                 7 (11.3)
   \>= 2 cm, \<5cm                        40 (64.5)
   \>= 5cm                                15 (24.2)
  Gender                                  
   Male                                   46 (74.2)
   Female                                 16 (25.8)
  Tumor stage                             
   T1/T2                                  41 (66.1)
   T3/T4                                  21 (33.9)
  Historical Grade                        
   G1/G2                                  39 (62.9)
   G3/G4                                  23 (37.1)
  --------------------------------------- -----------

![**The validation of the expression patterns and the methylation status of SNHG3 and SNHG15.** (**A**) q-RT-PCR analysis of SNHG3 and SNHG15 expression in ccRCC and adjacent normal renal tissues. (**B**) Patients were grouped according to the median cutoff of SNHG3 and SNHG15 expression for OS detection, patients were grouped according to the median cutoff of SNHG15 expression for RFS detection, and the correlation between SNHG3 and SNHG15 expression and the tumor stage of ccRCC patients. (**C**) Pyrosequencing analysis of cg07807470, cg15161854, cg00953154 and cg16459265 methylation levels between ccRCC and matched adjacent normal tissues. (**D**) The methylation levels of cg07807470 and cg15161854 were negatively associated with the expression of SNHG3. (**E**) The methylation levels of cg00953154 and cg16459265 were negatively associated with the expression of SNHG15. (**F**) Patients were grouped according to the median cutoff of cg15161854 and cg16459265 methylation status for OS detection. (**G**) Patients were grouped according to the median cutoff of cg15161854 and cg16459265 methylation status for RFS detection.](aging-12-102894-g007){#f7}

In addition, the methylation status of 4 CpG sites (cg07807470, cg15161854, cg00953154 and cg16459265) in 15 paired clinical samples were tested through pyrosequencing. In the whole population, the methylation levels of 4 methylation sites were consistent with the TCGA cohort. The methylation levels of cg07807470, cg15161854, cg00953154 and cg16459265 were significantly lower in ccRCC compared with adjacent normal tissues ([Figure 7C](#f7){ref-type="fig"}). The representative results of pyrosequencing for methylation status in two paired samples were shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. Besides, the methylation levels of cg07807470 (r=-0.5662) and cg15161854 (r=-0.6244) were significantly negatively correlated with SNHG3 expression ([Figure 7D](#f7){ref-type="fig"}), while the methylation levels of cg00953154 (r=-0.5461) and cg16459265 (r=-0.6629) were negatively associated with SNHG15 expression ([Figure 7E](#f7){ref-type="fig"}), which were consistent with the results from the TCGA datasets. Furthermore, the methylation levels of cg15161854 with a higher correlation with SNHG3 expression and cg16459265 with a higher correlation with SNHG15 expression in another 36 available ccRCC samples were tested through pyrosequencing for survival analysis. Consistent with the survival analysis results of TCGA samples, our results showed that low methylation levels of cg15161854 and cg16459265 were associated with the shorter OS ([Figure 7F](#f7){ref-type="fig"}) and RFS ([Figure 7G](#f7){ref-type="fig"}) of ccRCC patients.

DISCUSSION
==========

Because nearly 1/3 of ccRCC patients have localized or distant metastasis at the initial diagnosis and almost all ccRCC show radiotherapy and chemotherapy resistance finally, the 5-year survival rates of ccRCC patients remains as low as 20% \[[@r6], [@r24], [@r25]\]. Therefore, finding new and effective prognostic biomarkers is critical for patients with ccRCC due to the disappointing clinical outcomes.

The past few years have seen the emergence of certain snoRNAs as potential regulators of cell fate, and insight into the molecular mechanisms by which snoRNAs may carry out these regulatory functions, in addition to the modification of rRNAs, has started to appear in the scientific literature \[[@r26]\]. Interestingly, the modification of ribosomal biogenesis was associated with the development of cancer, suggesting that the classical function of snoRNA may contribute to the development of cancer \[[@r27], [@r28]\]. In addition to the initial evidence of snoRNA involvement in cancer development, increasing evidence has demonstrated that dysregulated small nucleolar RNA host genes may contribute to multiple cancer progression. For example, SNHG1 was upregulated in human colorectal cancer tissues, and high SNHG1 expression was associated with shorter OS \[[@r29]\]; SNHG1 contributed to sorafenib resistance by activating the Akt pathway in hepatocellular carcinoma cells \[[@r30]\]; SNHG17 was upregulated in non-small-cell lung cancer (NSCLC), and the knockdown of SNHG17 inhibited the proliferation and migration and promoted the apoptosis of NSCLC cells \[[@r31]\]. However, there has been relatively little research on the clinical roles of small nucleolar RNA host genes in ccRCC.

In our study, we compared the expression patterns of 20 small nucleolar RNA host genes in ccRCC and adjacent normal tissues based on TCGA-KIRC data. Results showed that compared with adjacent normal tissues, SNHG1, GAS5, SNHG3-8, SNHG11, SNHG12, SNHG15-17, SNHG20, SNHG22 and SNHG25 were significantly upregulated in ccRCC tissues, while SNHG9, SNHG10, DANCR and SNHG14 were remarkably downregulated in ccRCC tissues. Moreover, after adjustment for confounding factors, increased SNHG3 expression was a potential risk factor of shorter OS, while upregulated SNHG15 expression was an independent predictor of shorter RFS in ccRCC. When concerning the relationship between these lncRNAs and the progression of ccRCC, SNHG3 and SNHG15 were closely related to some clinical parameters of ccRCC, such as tumor stage, histological grade and remote metastasis. In addition, we also performed q-RT-PCR to verify the expression of SNHG3 and SNHG15 with 62 paired clinical samples. Results of the log-rank test showed that high expression of SNHG3 and SNHG15 was associated with the shorter OS, and the expression levels of SNHG3 and SNHG15 were significantly higher in advanced-stage ccRCC than in early-stage ccRCC. Although survival data from both the validation samples and the TCGA samples showed that the prognosis of ccRCC patients with high expression of SNHG3 and SNHG15 was poor, the median survival time of validation patients was much shorter than that of TCGA patients (about 1000 days vs. 1800-2000 days). Clinically, approximately 30% of localized ccRCC patients will nevertheless develop recurrence or metastasis after surgical resection of their tumor \[[@r32]\]. At present, several prognostic factors for patients with recurrent RCC after a nephrectomy for localized disease were established. In a previous study, each RCC patient was given a total risk score of 0 to 5, with one point for each of five prognostic variables (recurrence \< 12 months after nephrectomy, serum calcium \> 10 mg/dL, hemoglobin \< lower limit of normal, lactate dehydrogenase \> 1.5x upper limit of normal, and Karnofsky performance status \< 80%), and patients were categorized into low- (score = 0), intermediate- (score = 1 to 2), and high-risk subgroups (score = 3 to 5) \[[@r33]\]. The result showed that the median survival time for low-risk, intermediate-risk, and high-risk patients was 76, 25, and 6 months, respectively. Therefore, in addition to the above 5 factors, more studies are needed on the impact of other factors, such as living environment, underlying diseases and medical conditions, on the median survival time of RCC patients.

Consistent with our results, SNHG3 and SNHG15 have been reported to be significantly upregulated in several types of cancer. SNHG3 was overexpressed in colorectal cancer \[[@r34]\], ovarian cancer \[[@r35]\], osteosarcoma \[[@r36]\] and hepatocellular carcinoma \[[@r37]\], and its upregulation was associated with poor OS. Moreover, a recent study demonstrated that the higher expression of SNHG3 could predict worse clinical prognosis, and knockdown of SNHG3 could significantly inhibit the proliferation and metastasis of ccRCC *in vitro* and *in vivo* \[[@r38]\]. Similarly, SNHG15 was also overexpressed in colorectal cancer \[[@r22], [@r39]\], thyroid carcinoma \[[@r40]\] and osteosarcoma \[[@r41]\]. Besides, SNHG15 could promote cell proliferation, invasion and drug resistance in colorectal cancer, suggesting its potential as prognostic marker and target for RNA-based therapies \[[@r42]\]. Furthermore, SNHG15 was significantly upregulated in RCC tissues and cell lines compared with its adjacent normal tissues and a proximal tubule epithelial cell line, and SNHG15 knockdown could inhibit RCC proliferation, invasion and migration \[[@r43]\]. Taken together, all the results indicated that the highly expressed SNHG3 and SNHG15 played crucial roles in the occurrence and development of ccRCC.

Epigenetic alterations such as DNA methylation, histone modification, and loss of genome imprinting play crucial roles in the formation and progression of cancer \[[@r44]\]. Over the past decade, many researches have indicated the presence of abnormal DNA methylation in various types of tumor \[[@r45]--[@r47]\]. In addition, it is well known that abnormal DNA methylation includes global hypomethylation and regional hypermethylation, in which regional hypermethylation is usually associated with gene silencing. For example, hypermethylation of the CpG shore of the Shh gene resulted in Shh loss, and inhibition of DNA methylation increased Shh expression to halt the initiation of bladder cancer at the early stage of progression \[[@r48]\]; DNA methylation at an enhancer of the three prime repair exonuclease 2 gene (TREX2) was linked to decreased TREX2 gene expression and protein expression, which may affect drug-induced DNA damage repair in laryngeal cancer \[[@r49]\]; and Epigenetic Silencing of miRNA-338-5p and miRNA-421 drived SPINK1-Positive Prostate Cancer \[[@r50]\]. Besides, a recent study reported that downregulation of CLDN7 due to promoter hypermethylation contributed to human ccRCC progression and poor prognosis \[[@r51]\], indicating DNA methylation may also play vital roles in ccRCC. However, all of above studies have focused on the effect of DNA methylation on mRNA or miRNA, and the regulation of DNA methylation on lncRNA was rarely reported.

During our study, we examined the correlation between SNHG3, SNHG15, SNHG12 and SNHG17 expression and their DNA methylation status. Results showed that the expression levels of SNHG3 and SNHG15 were more likely to be modulated by methylation in ccRCC. The methylation levels of cg07807470 and cg15161854 were negatively associated with SNHG3 expression, and the methylation levels of cg00953154, cg03440944 and cg16459265 were negatively correlated with SNHG15 expression in ccRCC. Moreover, low methylation levels of cg07807470, cg15161854, cg00953154 and cg16459265 were significantly associated with poor OS of ccRCC patients. Low methylation levels of cg07807470, cg15161854 and cg16459265 were also related to the shorter RFS. In addition, we verified the methylation status of the 4 CpG sites and their correlation with their corresponding SNHGs with 15 paired clinical samples by pyrosequencing and q-RT-PCR. Furthermore, the methylation levels of cg15161854 with a higher correlation with SNHG3 expression and cg16459265 with a higher correlation with SNHG15 expression in another 36 available ccRCC samples were tested through pyrosequencing for survival analysis. Consistent with the survival analysis results of TCGA samples, our results showed that low methylation levels of cg15161854 and cg16459265 were associated with the shorter OS and RFS of ccRCC patients. Taken together, SNHG3 and SNHG15 expression levels might be substantially modulated by DNA methylation in ccRCC.

In summary, we for the first time comprehensively determined the clinical significance of small nucleolar RNA host genes and the effect of DNA methylation on their expression in ccRCC. Although, we identified that SNHG3 and SNHG15 may have great clinical value to act as diagnostic biomarkers and indicators to evaluate the survival and progression of ccRCC, the number of cases can still be improved. Currently, the mechanisms of SNHG3 and SNHG15 in regulating the prognosis of patients with ccRCC are still not fully understood. More experiments are needed to further validate the regulation of DNA methylation on SNHG3 and SNHG15 expression.

MATERIALS AND METHODS
=====================

Ethics statement
----------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Biomedical Research Ethics Committee of Peking University First Hospital.

TCGA datasets
-------------

Level-3 RNA-sequencing data, the clinicopathological and survival data of patients with ccRCC were downloaded from TCGA (<https://portal.gdc.cancer.gov/>). The data availability of the patients included were summarized in [Figure 1](#f1){ref-type="fig"}. Briefly, 539 ccRCC and 72 adjacent normal renal tissues were included in this study. Their clinical and survival data, including tumor stage, lymph node, metastasis, pathological stage, neoplasm histologic grade, OS and RFS, were downloaded. In addition, DNA methylation data (measured by the Infinium Human- Methylation450 BeadChip) that contains the data of 325 ccRCC and 160 adjacent normal renal tissues were also downloaded.

Clinical samples for validation
-------------------------------

A total of 62 paired tissues samples (adjacent normal renal tissue and ccRCC) were collected from ccRCC patients who underwent radical or partial nephrectomy at Peking University First Hospital. All the samples were immediately snap frozen in liquid nitrogen for long-term preservation until RNA or DNA extraction. This study was approved by the Biomedical Research Ethics Committee of Peking University First Hospital (Beijing, China, IRB00001052-18004). Written informed consent was also obtained from all patients.

Total RNA extraction and quantitative real-time PCR
---------------------------------------------------

Total RNA was extracted from the 124 tissue samples using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific Inc.), according to the manufacturer's instructions. cDNA was generated using reverse transcription (TansGEN, Beijing, China). q-RT-PCR was performed using the ABI PRISM 7000 Fluorescent Quantitative PCR System (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions, and normalized to GAPDH. All experiments were repeated at least three times. The detailed primer sequences included in this study are shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Pyrosequencing
--------------

Genomic DNA was extracted from 15 paired clinical samples using the QIAamp DNA FFPE Tissue kit (QIAGEN, Hilden, Germany). The concentration and purity of these DNA samples were determined with a spectrophotometer (NANO-DROP 2000, Thermo Scientific, Waltham, MA, USA). Bisulfite conversion of total 500 ng purified DNA in each sample was performed with QIAGEN 59124-EpiTect Plus DNA Bisufite Kit according to manufacturer's instructions. The bisulfite conversed DNA was amplified with Kapa Biosystems Hs Polymerase With Dntps250u KK5516 (KAPA, USA) with reaction setup: 34.8ul PCR-grade water, 10ul 5x KAPA buffer, 1ul dNTP (10Mm/each), 1ul forward prime (50pM/ul), 1ul reverse primers (50pM/ul), 2ul bisulfite-treated DNA (25ng) and 0.2ul Taq (5U/ul) in total 50 μL each reaction and with following thermal cycle condition: initial denaturation at 95 °C for 3 mins, denaturation at 94 °C for 30 s, annealing at 50 °C for 30 s, extension at 72 °C for 1 min executed for 40 cycles followed by extension at 72 °C for 7 min and hold at 4 °C. The amplicons were then subjected to pyrosequencing with PyroMark Q96 ID (Qiagen, Hilden, Germany). All primers used are presented in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Statistical analysis
--------------------

Welch's unequal variances t-test was used to detect differences in continuous variables. The Pearson's correlation test was conducted to assess the correlations between lncRNAs and hypoxia. The extent of correlations between the expression of SNHG3, SNHG12 and SNHG17 and their CpG sites' DNA methylation levels were also evaluated. The receiver operating characteristic (ROC) curve was used to assess the diagnostic effectiveness of these aberrantly expressed lncRNAs in ccRCC. The prognostic roles of lncRNAs were examined with the Kaplan--Meier method, and the log-rank test was conducted to determine the significance of the difference between the survival curves. The univariate and multivariate cox analyses of these lncRNAs were also performed. A P-value \< 0.05 represented statistical significance. The statistical analyses were all carried out by R language and GraphPad Prism 7.00.
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======================
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